Expert Review on the Multidisciplinary Management of Bladder Cancer

Expert Review on the Multidisciplinary Management of Bladder Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Introduction: Neoadjuvant Chemotherapy in Bladder Cancer

March 27th 2015

EP. 2: Lymph Node Dissection in Bladder Cancer

March 27th 2015

EP. 3: Managing Renal Pelvis Transitional Cell Carcinoma

March 27th 2015

EP. 4: Neoadjuvant and Adjuvant Therapy in Bladder Cancer

March 27th 2015

EP. 5: Multidisciplinary Approach in Muscle-Invasive Bladder Cancer

March 27th 2015

EP. 6: Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

EP. 7: Treating Relapsed Muscle-Invasive Bladder Cancer

March 27th 2015

EP. 8: Potential Targets in Muscle-Invasive Bladder Cancer

March 27th 2015

EP. 9: Anti-PD-L1 Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

EP. 10: Novel Therapies Needed for Muscle-Invasive Bladder Cancer

March 27th 2015

Trending on OncLive

Pumitamig Plus Elfetabart Drozuntecan Elicits 70% ORR Across Lines of Therapy in SCLC

SERENA-4 Misses Primary PFS End Point With Camizestrant Plus Palbociclib in First-Line ER+ Advanced Breast Cancer

Dibotatug Is Safe and Yields Durable Responses in Large Granular Lymphocytic Leukemia

Asciminib Maintains Superior MMR and Favorable Safety at 3 Years in Newly Diagnosed Ph+ CML

Extended-Interval Tarlatamab Yields Comparable Exposure, Survival to Q2W Dose in Previously Treated SCLC